Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.
BACKGROUND
The efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder (ADHD) shows wide between-study variability, which yields heterogeneous results in meta-analysis. The reasons for this variability have not been comprehensively investigated.


OBJECTIVE
To determine the influence of treatment-related covariates of methylphenidate for adults with ADHD by means of meta-analysis. Clinical and methodological moderators and clinical trial reporting quality were also collected to control for their potential confounding effect.


METHODS
We searched for randomized, placebo-controlled clinical trials investigating the efficacy of methylphenidate for adults with ADHD. The study outcome was the efficacy of methylphenidate for reducing ADHD symptom severity. Treatment-related covariates included dose, type of drug-release formulation (formulations with a continuous drug release vs those with a non-continuous drug release), dose regimen (fixed vs flexible) and treatment length. Clinical (presence of co-morbid substance use disorders [SUD]) and methodological (design and rater) covariates were also collected, in addition to clinical trial reporting quality. The standardized mean difference (SMD) was calculated for each study. The analysis of the influence of methylphenidate effect modifiers was performed by means of random-effects meta-regression.


RESULTS
Eighteen studies were included. Dose, type of formulation and SUD appeared to modify the efficacy of methylphenidate in the bivariate analysis. These variables were included in a multivariate meta-regression, which showed that methylphenidate, at an average dose of 57.4 mg/day, delivered by means of non-continuous-release formulations, had a moderate effect on ADHD symptoms compared with placebo (SMD 0.57-0.58). A dose-response relationship was found, indicating that efficacy could be increased by SMD 0.11-0.12 for every 10 mg increment of methylphenidate. Continuous-release formulations and co-morbid SUD appeared to reduce the efficacy of methylphenidate. Nevertheless, the effect of treatment formulation may have been confounded by co-morbid SUD, since all studies using this continuous-release formulation were conducted in dual ADHD-SUD patients. No residual heterogeneity was found.


CONCLUSIONS
This study shows that methylphenidate improves ADHD symptoms in adults in a dose-dependent fashion. The efficacy of methylphenidate appears to be reduced in patients with co-morbid SUD. It is unclear whether methylphenidate efficacy is influenced by the type of formulation, because the effect of this covariate is confounded by that of co-morbid SUD.
Psychiatry Department, Hospital Universitari Vall dHebron, Barcelona, Spain. xavier.castells@udg.edu
Xavier
X
Castells
Josep Antoni
JA
Ramos-Quiroga
David
D
Rigau
Rosa
R
Bosch
Mariana
M
Nogueira
Xavier
X
Vidal
Miguel
M
Casas
D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D015897:Comorbidity; D003692:Delayed-Action Preparations; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D019966:Substance-Related Disorders / Q000453:epidemiology; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D008774:Methylphenidate
J Clin Pharmacol. 2000 Apr;40(4):379-88
10761165
Clin Neuropharmacol. 1985;8(4):343-56
4075304
Psychopharmacology (Berl). 2008 Mar;197(1):1-11
18026719
J Atten Disord. 2002 Sep;6(2):49-60
12142861
Clin Pharmacol Ther. 1999 Sep;66(3):295-305
10511066
Arch Gen Psychiatry. 1984 Nov;41(11):1059-63
6388523
Drugs. 2003;63(22):2395-411
14609347
Int J Epidemiol. 2002 Feb;31(1):140-9
11914310
Psychol Med. 2004 Aug;34(6):973-82
15554568
Can J Psychiatry. 2003 Sep;48(8):546-54
14574830
Biol Psychiatry. 2008 May 15;63(10):981-9
18206857
Clin Ther. 2008 Jan;30(1):59-69
18343243
J Psychopharmacol. 2009 Sep;23(7):733-44
18562416
Am J Psychiatry. 1993 Dec;150(12):1792-8
8238632
Am J Psychiatry. 1985 May;142(5):547-52
3885760
J Clin Psychiatry. 2007 Feb;68(2):268-77
17335326
Biol Psychiatry. 2006 May 1;59(9):829-35
16373066
Stat Med. 2000 Nov 30;19(22):3127-31
11113947
Drug Alcohol Depend. 2006 Feb 1;81(2):137-48
16102908
Ann Pharmacother. 2003 Dec;37(12):1884-90
14632541
J Clin Psychopharmacol. 2009 Jun;29(3):239-47
19440077
J Clin Psychiatry. 2007 Jan;68(1):93-101
17284136
Behav Brain Res. 1998 Jul;94(1):127-52
9708845
Int J Neuropsychopharmacol. 2009 Sep;12(8):1137-47
19580697
Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I93-101
15322960
J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S54-61
18480678
Am J Addict. 2007;16 Suppl 1:45-54; quiz 55-6
17453606
Biol Psychiatry. 2007 Jun 15;61(12):1380-7
17137560
BMJ. 1994 Nov 19;309(6965):1351-5
7866085
MedGenMed. 2006 Oct 05;8(4):4
17415287
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
J Clin Psychopharmacol. 2004 Feb;24(1):24-9
14709943
Addiction. 2005 Dec;100(12):1868-74
16367988
Psychopharmacology (Berl). 1997 May;131(1):71-8
9181638
J Occup Environ Med. 2005 Jun;47(6):565-72
15951716
BMJ. 1997 Dec 13;315(7122):1610-4
9437284
Synapse. 2004 Sep 1;53(3):168-75
15236349
Ann Clin Psychiatry. 2001 Sep;13(3):129-34
11791949
J Clin Psychiatry. 2006;67 Suppl 8:38-45
16961429
Exp Clin Psychopharmacol. 2002 Aug;10(3):286-94
12233989
Clin Pharmacokinet. 2003;42(4):393-401
12648029
Psychol Med. 2006 Feb;36(2):167-79
16420713
Int J Clin Pharmacol Ther. 2002 Apr;40(4):175-84
11996212
CNS Drugs. 2003;17(2):117-31
12521359
CNS Drugs. 2008;22(7):603-11
18547128
J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921
17581453
Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9
19165529
Drugs. 2002;62(15):2251-9; discussion 2260-1
12381228
JAMA. 2004 Aug 4;292(5):619-23
15292088
Biol Psychiatry. 2005 Mar 1;57(5):456-63
15737659
Arch Gen Psychiatry. 1995 Jun;52(6):434-43
7771913
Drug Alcohol Depend. 2007 Feb 23;87(1):20-9
16930863
J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):989-1002
17667478
Int J Neuropsychopharmacol. 2004 Mar;7(1):77-97
14733627